ZERO WORLD RESEARCHアミノ酸・有機酸の学術文献データベース

Cardiomyocyte-derived small extracellular vesicles can signal eNOS activation in cardiac microvascular endothelial cells to protect against Ischemia/Reperfusion injury.

心筋細胞由来の小型細胞外小胞は心臓微小血管内皮細胞におけるeNOS活性化をシグナル伝達し、虚血再灌流障害を防ぐ (機械翻訳の邦題)

Theranostics2020Chen G, Xu C, Gillette TG, et al.
研究デザインその他の原著論文
対象ヒト・動物 併記

記録の確認項目

研究デザイン
その他の原著論文
対象
ヒト・動物 併記
出版年
2020
出典
doi.org
抄録の表示
表示あり
出版状態
有効な記録
状態確認日
2026/08/17
収集日
2026/08/03
鮮度
確認期限内
確認段階
自動処理
記録状態
公開

日本語要約(機械生成)

本研究は、心筋細胞と心臓微小血管内皮細胞間のクロストークが虚血再灌流障害に対する保護に果たす役割を解明することを目的とした。通心絡が内皮細胞のeNOS活性化を介して心筋保護作用を示すが、その活性化は心筋細胞由来の小型細胞外小胞を介して間接的に起こることを見出した。通心絡処理により心筋細胞由来の小型細胞外小胞中のLinc-RORが増加し、内皮細胞に取り込まれるとmiR-145-5pを低下させ、p70s6k1の発現を促進してeNOS経路を活性化する。この活性化は内皮細胞と心筋細胞の両方の生存を高め、心臓の虚血再灌流障害後の生存率を向上させる。これらの知見は、心筋細胞と内皮細胞のクロストークによる心保護機構を明らかにし、新たな治療標的を示すものである。

この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。

抄録

Rationale: The crosstalk between cardiac microvascular endothelial cells (CMECs) and cardiomyocytes (CMs) has emerged as a key component in the development of, and protection against, cardiac diseases. For example, activation of endothelial nitric oxide synthase (eNOS) in CMECs, by therapeutic strategies such as ischemic preconditioning, plays a critical role in the protection against myocardial ischemia/reperfusion (I/R) injury. However, much less is known about the signals produced by CMs that are able to regulate CMEC biology. Here we uncovered one such mechanism using Tongxinluo (TXL), a traditional Chinese medicine, that alleviates myocardial ischemia/reperfusion (I/R) injury by activating CMEC eNOS. The aim of our study is to identify the signals produced by CMs that can regulate CMEC biology during I/R. Methods:Ex vivo, in vivo, and in vitro settings of ischemia-reperfusion were used in our study, with the protective signaling pathways activated in CMECs identified using genetic inhibition (p70s6k1 siRNA, miR-145-5p mimics, etc.), chemical inhibitors (the eNOS inhibitor, L-NNA, and the small extracellular vesicles (sEVs) inhibitor, GW4869) and Western blot analyses. TritonX-100 at a dose of 0.125% was utilized to inactivate the eNOS activity in endothelium to investigate the role of CMEC-derived eNOS in TXL-induced cardioprotection. Results: We found that while CMEC-derived eNOS activity was required for the cardioprotection of TXL, activation of eNOS in CMECs by TXL did not occur directly. Instead, eNOS activation in CMECs required a crosstalk between CMs and CMECs through the uptake of CM-derived sEVs. We further demonstrate that TXL induced CM-sEVs contain increased levels of Long Intergenic Non-Protein Coding RNA, Regulator Of Reprogramming (Linc-ROR). Upon uptake into CMECs, linc-ROR downregulates its target miR-145-5p leading to activation of the eNOS pathway by facilitating the expression of p70s6k1 in these cells. The activation of CMEC-derived eNOS works to increase survival in both the CMECs and the CMs themselves. Conclusions: These data uncover a mechanism by which the crosstalk between CMs and CMECs leads to the increased survival of the heart after I/R injury and point to a new therapeutic target for the blunting of myocardial I/R injury.

MeSH

Aniline CompoundsAnimalsBenzylidene CompoundsCardiotonic AgentsCell CommunicationCells, CulturedCoronary VesselsDisease Models, AnimalDrugs, Chinese HerbalEndothelial CellsEndothelium, VascularExtracellular VesiclesHumansIsolated Heart PreparationMaleMicrovesselsMyocardial Reperfusion InjuryMyocytes, CardiacNitric Oxide Synthase Type IIINitroarginineRatsSignal Transduction

DOI 10.7150/thno.43163

PMID 33052245

原文・出典を見る →